Eisai has announced the launch of Fycompa (perampanel) in Spain, where it is indicated for the adjunctive treatment of partial-onset seizures, with or without secondary generalised seizures, in patients with epilepsy aged 12 years and older. The launch follows approval for reimbursement, which was based on three randomised, double-blind, placebo-controlled and dose-escalated global pivotal Phase III studies (304, 305, and 306), as well as an open-label extension study (307).